WO2008099874A1 - ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 - Google Patents

ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 Download PDF

Info

Publication number
WO2008099874A1
WO2008099874A1 PCT/JP2008/052425 JP2008052425W WO2008099874A1 WO 2008099874 A1 WO2008099874 A1 WO 2008099874A1 JP 2008052425 W JP2008052425 W JP 2008052425W WO 2008099874 A1 WO2008099874 A1 WO 2008099874A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazine derivative
pharmaceutical composition
combination
treatment
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052425
Other languages
English (en)
French (fr)
Inventor
Masako Maekawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HRP20130111AT priority Critical patent/HRP20130111T1/hr
Priority to CA2677905A priority patent/CA2677905C/en
Priority to BRPI0807597A priority patent/BRPI0807597B8/pt
Priority to ES08711267T priority patent/ES2396595T3/es
Priority to CN200880005061XA priority patent/CN101610772B/zh
Priority to MX2009008779A priority patent/MX2009008779A/es
Priority to SI200830895T priority patent/SI2123276T1/sl
Priority to JP2008558114A priority patent/JP5255456B2/ja
Priority to NZ578989A priority patent/NZ578989A/en
Priority to KR20097017506A priority patent/KR101479083B1/ko
Priority to PL08711267T priority patent/PL2123276T3/pl
Priority to AU2008215397A priority patent/AU2008215397B2/en
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Priority to DK08711267.8T priority patent/DK2123276T3/da
Priority to US12/527,260 priority patent/US8759354B2/en
Priority to EP08711267A priority patent/EP2123276B1/en
Publication of WO2008099874A1 publication Critical patent/WO2008099874A1/ja
Priority to IL200285A priority patent/IL200285A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

一般式 「式中、Ｒ１およびＲ２は、同一または異なって水素原子またはハロゲン原子を；Ｒ３は、水素原子またはアミノ保護基を示す。」で表されるピラジン誘導体またはその塩ならびに一種以上のノイラミニダーゼ阻害剤を含有する医薬組成物は、インフルエンザの治療または予防などの処置に有用であり、これらを組み合わせて使用する方法は、インフルエンザの治療または予防などの処置に有用である。
PCT/JP2008/052425 2007-02-16 2008-02-14 ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 Ceased WO2008099874A1 (ja)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA2677905A CA2677905C (en) 2007-02-16 2008-02-14 Pharmaceutical composition comprising pyrazine derivatives and neuraminidase inhibitors for treating influenza infections
BRPI0807597A BRPI0807597B8 (pt) 2007-02-16 2008-02-14 composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação
ES08711267T ES2396595T3 (es) 2007-02-16 2008-02-14 Composición farmacéutica que contiene un derivado de pirazina y método de utilización de un derivado de pirazina en combinación
CN200880005061XA CN101610772B (zh) 2007-02-16 2008-02-14 包含吡嗪衍生物的药物组合物和使用吡嗪衍生物的联合用药的方法
MX2009008779A MX2009008779A (es) 2007-02-16 2008-02-14 Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
SI200830895T SI2123276T1 (sl) 2007-02-16 2008-02-14 Farmacevtska sestava, vsebujoča derivat pirazina,in postopek z uporabo derivata pirazina v kombinaciji
JP2008558114A JP5255456B2 (ja) 2007-02-16 2008-02-14 ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法
KR20097017506A KR101479083B1 (ko) 2007-02-16 2008-02-14 피라진 유도체를 함유하는 의약조성물 및 피라진 유도체를 조합하여 사용하는 방법
NZ578989A NZ578989A (en) 2007-02-16 2008-02-14 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
HRP20130111AT HRP20130111T1 (hr) 2007-02-16 2008-02-14 Farmaceutski pripravak koji sadržava derivat pirazina i postupak upotrebe derivata pirazina u kombinaciji
AU2008215397A AU2008215397B2 (en) 2007-02-16 2008-02-14 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
PL08711267T PL2123276T3 (pl) 2007-02-16 2008-02-14 Kompozycja farmaceutyczna zawierająca pochodną pirazyny oraz sposób stosowania pochodnej pirazyny w kombinacji
DK08711267.8T DK2123276T3 (da) 2007-02-16 2008-02-14 Farmaceutisk sammensætning omfattende pyrazinderivat og fremgangsmåde til anvendelse af et pyraziderivat i kombination
US12/527,260 US8759354B2 (en) 2007-02-16 2008-02-14 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
EP08711267A EP2123276B1 (en) 2007-02-16 2008-02-14 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
IL200285A IL200285A (en) 2007-02-16 2009-08-06 Pharmaceutical preparation containing a pirazine derivative and its use in combination with one or more neuromidase inhibitors for the preparation of a preparation for the treatment of influenza virus infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-035975 2007-02-16
JP2007035975 2007-02-16

Publications (1)

Publication Number Publication Date
WO2008099874A1 true WO2008099874A1 (ja) 2008-08-21

Family

ID=39690101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052425 Ceased WO2008099874A1 (ja) 2007-02-16 2008-02-14 ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法

Country Status (21)

Country Link
US (1) US8759354B2 (ja)
EP (1) EP2123276B1 (ja)
JP (1) JP5255456B2 (ja)
KR (1) KR101479083B1 (ja)
CN (1) CN101610772B (ja)
AU (1) AU2008215397B2 (ja)
BR (1) BRPI0807597B8 (ja)
CA (1) CA2677905C (ja)
CY (1) CY1113435T1 (ja)
DK (1) DK2123276T3 (ja)
ES (1) ES2396595T3 (ja)
HR (1) HRP20130111T1 (ja)
IL (1) IL200285A (ja)
MX (1) MX2009008779A (ja)
NZ (1) NZ578989A (ja)
PL (1) PL2123276T3 (ja)
PT (1) PT2123276E (ja)
RU (1) RU2463051C2 (ja)
SI (1) SI2123276T1 (ja)
WO (1) WO2008099874A1 (ja)
ZA (1) ZA200905536B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501718A (ja) * 2010-11-18 2014-01-23 アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2016518451A (ja) * 2013-05-14 2016-06-23 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗インフルエンザ組成物及び方法
WO2020138067A1 (ja) 2018-12-25 2020-07-02 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤
JPWO2021241613A1 (ja) * 2020-05-27 2021-12-02

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388333A (zh) * 2009-04-09 2012-03-21 Lg电子株式会社 显示装置
AU2011250970B2 (en) * 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
MY161429A (en) * 2010-09-30 2017-04-14 Toyama Chemical Co Ltd Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
CN104817511B (zh) * 2015-04-27 2017-04-19 济南大学 一种丁烯二酸酐制备法匹拉韦关键中间体的方法
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP7778685B2 (ja) * 2020-04-30 2025-12-02 富士フイルム富山化学株式会社 ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (ja) * 1988-01-29 1989-08-09 Dso Pharmachim 抗ウイルス薬
WO2000010569A1 (en) * 1998-08-20 2000-03-02 Toyama Chemical Co., Ltd. Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both
WO2003015798A1 (fr) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Nouvelle methode virocide/inhibitrice de la proliferation virale et nouvel analogue de pyradine nucleotide/pyradine nucleoside
WO2010000569A2 (de) 2008-07-04 2010-01-07 Henkel Ag & Co. Kgaa Haarkonditionierende mittel mit imidazolinen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005354833A (ja) * 2004-06-11 2005-12-22 Fujinon Corp アクチュエータ
JP4689989B2 (ja) * 2004-08-27 2011-06-01 オリンパス株式会社 振動波リニアモータ及びそれを用いたレンズ装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (ja) * 1988-01-29 1989-08-09 Dso Pharmachim 抗ウイルス薬
WO2000010569A1 (en) * 1998-08-20 2000-03-02 Toyama Chemical Co., Ltd. Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both
WO2003015798A1 (fr) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Nouvelle methode virocide/inhibitrice de la proliferation virale et nouvel analogue de pyradine nucleotide/pyradine nucleoside
WO2010000569A2 (de) 2008-07-04 2010-01-07 Henkel Ag & Co. Kgaa Haarkonditionierende mittel mit imidazolinen

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 48, no. 12, 2004, pages 4855 - 4863 *
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 14, no. 5, 2003, pages 235 - 241 *
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 6, no. 2, 1995, pages 109 - 113 *
CHOU ET AL., ADVANCED ENZYME REGULATION, vol. 22, 1984, pages 27 - 55
DATABASE CAPLUS [online] GOVORKOVA E.A. ET AL.: "Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells", XP008111831, Database accession no. (2004:1065557) *
DATABASE CAPLUS [online] MADREN L.K. ET AL.: "In vitro inhibitory effects of combinations of anti-influenza agents", XP008111829, accession no. STN Database accession no. (1995:445031) *
DATABASE CAPLUS [online] SHIGETA S.: "Recent progress in anti-influenza chemotherapy", XP008111832, accession no. STN Database accession no. (1999:739739) *
DATABASE CAPLUS [online] TAKAHASHI K. ET AL.: "In vitro and in vivo activities of T-705 and oseltamivir against influenza virus", XP008111830, accession no. STN Database accession no. (2003:989463) *
DRUGS IN R & D, vol. 2, no. 3, pages 153 - 164 *
J. VIROL. METHODS, vol. 106, 2002, pages 71 - 79
JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 61, 2003, pages 1975 - 1979
PROC. NATL. ACAD. SCI., vol. 95, 1998, pages 8874 - 8849
See also references of EP2123276A4
TAIRA ET AL., ACTA MEDICA OKAYAMA, vol. 60, 2006, pages 25 - 34
W. GREENE ET AL.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC, pages: 494 - 653

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501718A (ja) * 2010-11-18 2014-01-23 アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
US10344055B2 (en) 2010-11-18 2019-07-09 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
JP2016518451A (ja) * 2013-05-14 2016-06-23 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗インフルエンザ組成物及び方法
WO2020138067A1 (ja) 2018-12-25 2020-07-02 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤
JPWO2021241613A1 (ja) * 2020-05-27 2021-12-02
WO2021241613A1 (ja) 2020-05-27 2021-12-02 富士フイルム富山化学株式会社 ピラジン誘導体とチオプリン誘導体を組み合わせてなるｒｎａウイルス感染症治療剤
JP7449379B2 (ja) 2020-05-27 2024-03-13 富士フイルム富山化学株式会社 ピラジン誘導体とチオプリン誘導体を組み合わせてなるｒｎａウイルス感染症治療剤

Also Published As

Publication number Publication date
AU2008215397B2 (en) 2012-09-06
JPWO2008099874A1 (ja) 2010-05-27
ZA200905536B (en) 2010-10-27
US20100087447A1 (en) 2010-04-08
CA2677905A1 (en) 2008-08-21
RU2009134516A (ru) 2011-03-27
HRP20130111T1 (hr) 2013-02-28
CN101610772B (zh) 2013-01-16
BRPI0807597B1 (pt) 2021-03-02
KR20090121289A (ko) 2009-11-25
PL2123276T3 (pl) 2013-04-30
JP5255456B2 (ja) 2013-08-07
KR101479083B1 (ko) 2015-01-07
RU2463051C2 (ru) 2012-10-10
EP2123276A4 (en) 2011-05-18
IL200285A (en) 2014-06-30
BRPI0807597B8 (pt) 2021-05-25
EP2123276A1 (en) 2009-11-25
IL200285A0 (en) 2010-04-29
PT2123276E (pt) 2013-01-16
DK2123276T3 (da) 2013-01-02
CN101610772A (zh) 2009-12-23
EP2123276B1 (en) 2012-11-28
AU2008215397A1 (en) 2008-08-21
CA2677905C (en) 2015-03-24
SI2123276T1 (sl) 2013-03-29
ES2396595T3 (es) 2013-02-22
CY1113435T1 (el) 2016-06-22
US8759354B2 (en) 2014-06-24
MX2009008779A (es) 2009-11-05
NZ578989A (en) 2011-07-29
BRPI0807597A2 (pt) 2014-05-06

Similar Documents

Publication Publication Date Title
WO2008099874A1 (ja) ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法
UA87250C2 (ru) Применение соединений пиперазина как гербицидов, средство, способ его получения и способ борьбы с нежелательным ростом растительности, соединения пиперазина, способ их получения (варианты) и промежуточные соединения
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
UA99908C2 (ru) Пиридопиразиновые производные, способ борьбы с растениями, гербицидные композиции
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2008108323A1 (ja) インフルエンザ治療剤
PH12012501689A1 (en) 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
TW200728307A (en) Novel spirochromanone derivatives
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
WO2010066629A3 (en) Novel azaindoles
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
WO2006116733A3 (en) Protein kinase inhibitors
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007080401A8 (en) Triazoloanilinopyrimidine derivatives for use as antiviral agents
WO2009069764A1 (ja) オピオイド鎮痛剤
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
WO2006078984A3 (en) Uses of methylphenidate derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880005061.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711267

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008558114

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200285

Country of ref document: IL

Ref document number: 2008215397

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5131/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2677905

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 578989

Country of ref document: NZ

Ref document number: 2008711267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12527260

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008779

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097017506

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008215397

Country of ref document: AU

Date of ref document: 20080214

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009134516

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0807597

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090812